Emergent Biosolutions EBITDA Margin 2010-2022 | EBS

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Emergent Biosolutions (EBS) over the last 10 years. The current EBITDA margin for Emergent Biosolutions as of March 31, 2022 is .
Emergent Biosolutions EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2022-03-31 $1.76B $0.39B 22.41%
2021-12-31 $1.79B $0.48B 26.83%
2021-09-30 $1.65B $0.46B 27.89%
2021-06-30 $1.71B $0.55B 32.36%
2021-03-31 $1.71B $0.66B 38.63%
2020-12-31 $1.56B $0.55B 35.41%
2020-09-30 $1.33B $0.37B 27.68%
2020-06-30 $1.26B $0.38B 29.92%
2020-03-31 $1.11B $0.24B 22.02%
2019-12-31 $1.11B $0.23B 20.52%
2019-09-30 $1.02B $0.16B 15.54%
2019-06-30 $0.88B $0.09B 10.58%
2019-03-31 $0.86B $0.15B 17.52%
2018-12-31 $0.78B $0.15B 19.54%
2018-09-30 $0.71B $0.18B 25.92%
2018-06-30 $0.68B $0.21B 30.40%
2018-03-31 $0.56B $0.15B 25.98%
2017-12-31 $0.56B $0.17B 29.95%
2017-09-30 $0.52B $0.16B 31.21%
2017-06-30 $0.51B $0.15B 29.24%
2017-03-31 $0.50B $0.14B 27.63%
2016-12-31 $0.49B $0.14B 29.45%
2016-09-30 $0.48B $0.18B 37.24%
2016-06-30 $0.49B $0.20B 41.38%
2016-03-31 $0.53B $0.23B 42.99%
2015-12-31 $0.49B $0.18B 36.20%
2015-09-30 $0.45B $0.17B 36.89%
2015-06-30 $0.43B $0.13B 31.16%
2015-03-31 $0.41B $0.12B 28.99%
2014-12-31 $0.40B $0.12B 29.95%
2014-09-30 $0.40B $0.07B 16.50%
2014-06-30 $0.35B $0.05B 13.96%
2014-03-31 $0.32B $0.05B 16.10%
2013-12-31 $0.31B $0.06B 19.87%
2013-09-30 $0.31B $0.06B 19.74%
2013-06-30 $0.29B $0.05B 17.77%
2013-03-31 $0.28B $0.04B 15.64%
2012-12-31 $0.28B $0.04B 14.89%
2012-09-30 $0.30B $0.06B 21.02%
2012-06-30 $0.29B $0.05B 18.47%
2012-03-31 $0.31B $0.06B 20.98%
2011-12-31 $0.27B $0.04B 14.96%
2011-09-30 $0.27B $0.03B 11.15%
2011-06-30 $0.28B $0.05B 16.90%
2011-03-31 $0.26B $0.04B 16.28%
2010-12-31 $0.29B $0.08B 27.62%
2010-09-30 $0.24B $0.05B 19.83%
2010-06-30 $0.21B $0.02B 10.68%
2010-03-31 $0.22B $0.03B 13.82%
2009-12-31 $0.24B $0.05B 19.15%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.592B $1.793B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.724B 9.84
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.093B 15.93
Biohaven Pharmaceutical Holding (BHVN) United States $9.948B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.434B 0.00
Arcus Biosciences (RCUS) United States $1.327B 33.64
Myovant Sciences (MYOV) United Kingdom $0.961B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.483B 0.00
Gelesis Holdings (GLS) United States $0.357B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.00
SQZ Biotechnologies (SQZ) United States $0.092B 0.00